Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic optionsa report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference

Europace

Volumn 14, Issue 1, 2012, Pages 8-27

  Kirchhof, Paulus ^a,b   Lip, Gregory Y H ^c   Van Gelder, Isabelle C ^d   Bax, Jeroen ^e   Hylek, Elaine ^f   Kaab, Stefan ^g   Schotten, Ulrich ^h   Wegscheider, Karl ⁱ   Boriani, Giuseppe ^j   Brandes, Axel ^k   Ezekowitz, Michael ^l   Diener, Hans ^m   Haegeli, Laurent ⁿ   Heidbuchel, Hein ^o   Lane, Deirdre ^c   Mont, Luis ^p   Willems, Stephan ⁱ   Dorian, Paul ^q   Aunes Jansson, Maria ^r   Blomstrom Lundqvist, Carina ^s   Borentain, Maria ^t   Breitenstein, Stefanie ^u   Brueckmann, Martina ^v   Cater, Nilo ^w   Clemens, Andreas ^v   Dobrev, Dobromir ^x   Dubner, Sergio ^y   Edvardsson, Nils G ^r   Friberg, Leif ^z   Goette, Andreas ^aa   Gulizia, Michele ^ab   Hatala, Robert ^ac   Horwood, Jenny ^ad   Szumowski, Lukas ^ae   Kappenberger, Lukas ^af   Kautzner, Josef ^ag   Leute, Angelika ^a,b   Lobban, Trudie ^ah   Meyer, Ralf ^b   Millerhagen, Jay ^ai   Morgan, John ^aj   Muenzel, Felix ^ak   Nabauer, Michael ^g   Baertels, Christoph ^u   Oeff, Michael ^al   Paar, Dieter ^am   Polifka, Juergen ^an   Ravens, Ursula ^ao   Rosin, Ludger ^am   Stegink, W ^ap   Steinbeck, Gerhard ^g   Vardas, Panos ^aq   Vincent, Alphons ^b   Walter, Maureen ^w   Breithardt, Günter ^a,b   Camm, A John ^ar   more..

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b AFNET ^*  (Switzerland)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY   (Netherlands)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MUNICH   (Germany)

^h MAASTRICHT UNIVERSITY   (Netherlands)

ⁱ UNIVERSITY OF HAMBURG   (Germany)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k ODENSE UNIVERSITY HOSPITAL   (Denmark)

^l THOMAS JEFFERSON UNIVERSITY   (United States)

^m UNIVERSITY OF DUISBURG ESSEN   (Germany)

ⁿ UNIVERSITY OF ZURICH   (Switzerland)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY OF BARCELONA   (Spain)

^q UNIVERSITY OF TORONTO   (Canada)

^r ASTRAZENECA R AND D   (Sweden)

^s UPPSALA UNIVERSITY   (Sweden)

^t BRISTOL MYERS SQUIBB   (United States)

^u BAYER AG   (Germany)

^v BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^w PFIZER INC   (United States)

^x UNIVERSITY OF HEIDELBERG   (Germany)

^y Clinica y Maternidad Suizo Argentina   (Argentina)

^z STOCKHOLM SÖDER HOSPITAL   (Sweden)

^aa St Vincenz Hospital   (Germany)

^ab Garibaldi Nesima Hospital   (Italy)

^ac NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^ad PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^ae INSTITUTE OF CARDIOLOGY   (Poland)

^af UNIVERSITY OF LAUSANNE   (Switzerland)

^ag INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^ah Atrial Fibrillation Association International   (United Kingdom)

^ai St Jude Medical Inc USA   (United States)

^aj UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^ak DAIICHI SANKYO CO   (Japan)

^al Klinikum Brandenburg   (Germany)

^am SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^an MSD Regional Business Support Center GmbH   (Germany)

^ao DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^ap AGA Medical Corporation   (Italy)

^aq UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^ar ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

antithrombotic therapy; atrial fibrillation; early therapy; management; outcomes; rate control; rhythm control; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DABIGATRAN; INTERLEUKIN 6; THROMBIN INHIBITOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CATHETER ABLATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; CORONARY STENT; COST BENEFIT ANALYSIS; DEVICE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG COST; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; EUROPE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FUNCTION; HEART MUSCLE FIBROSIS; HEART RATE; HEMATOLOGICAL PARAMETERS; HOLTER MONITORING; HUMAN; KIDNEY DISEASE; LABORATORY TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; RADIOFREQUENCY; RECURRENT DISEASE; RISK FACTOR; RISK REDUCTION; SCAR; STROKE; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RATS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 84055184415     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur241     Document Type: Conference Paper

References (227)

1. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC et al. Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 2007;9: 1006-23. (Pubitemid 351773289)
2. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R et al. Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 2009;11:860-85.
3. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation. Europace 2010;12:1360-420.
4. Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A et al. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. Circulation 2009;119:606-18.
5. Shotan A, Garty M, Blondhein DS, Meisel SR, Lewis BS, Shochat M et al. Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: Results from heart failure survey in Israel (HFSIS). Eur Heart J 2010;31:309-17.
6. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86-92.
7. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.
8. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40: 1636-44. (Pubitemid 35253642)
9. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
10. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: Reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008;10:21-7. (Pubitemid 351767271)
11. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41. (Pubitemid 24239044)
12. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96: 2455-61. (Pubitemid 27425856)
13. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F et al. Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003; 41:218-23. (Pubitemid 36204892)
14. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen RJ et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-31.
15. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB Sr et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet 2009;373:739-45.
16. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-71. (Pubitemid 46177437)
17. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. (Pubitemid 37553570)
18. Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation 2010;122:2009-15.
19. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85-91.
20. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167:928-34. (Pubitemid 46762755)
21. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
22. Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: Effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 2009;30:1113-20.
23. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009;119:2146-52.
24. Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr et al. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens 2008;21:1111-6.
25. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5. (Pubitemid 38747806)
26. Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson H et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708-12.
27. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK et al. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet 2010;42:240-4.
28. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-7. (Pubitemid 47080348)
29. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 2009;41:879-81.
30. Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: A longitudinal cohort study of 21 years. Eur Heart J 2008;29:2227-33.
31. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE et al. The long-And short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 2010;55: 2319-27.
32. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: The Danish Diet, Cancer, and Health Study. Am J Med 2005; 118:489-95. (Pubitemid 40615472)
33. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-7. (Pubitemid 39552671)
34. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med 2006;166:2322-8. (Pubitemid 44833356)
35. Watanabe H, Tanabe N,Watanabe T, Darbar D, Roden DM, Sasaki S et al. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circulation 2008;117:1255-60. (Pubitemid 351365676)
36. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, Larson MG et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA 2007;297:709-15. (Pubitemid 46294560)
37. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace 2008;10:15-20. (Pubitemid 351767264)
38. Stevenson IH, Teichtahl H, Cunnington D, Ciavarella S, Gordon I, Kalman JM. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J 2008;29: 1662-9. (Pubitemid 351957544)
39. Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation 2004;110: 364-7. (Pubitemid 38993843)
40. Sawin CT, Geller A,Wolf PA, Belanger AJ, Baker E, Bacharach P et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52. (Pubitemid 24333188)
41. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295:1033-41.
42. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop WC et al. High-normal thyroid function and risk of atrial fibrillation: The Rotterdam study. Arch Intern Med 2008;168:2219-24.
43. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA 2008;300: 2489-96.
44. Mukamal KJ, Psaty BM, Rautaharju PM, Furberg CD, Kuller LH, Mittleman MA et al. Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: The Cardiovascular Health Study. Am Heart J 2007;153:260-6. (Pubitemid 46096872)
45. Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008;102:1056-9.
46. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W et al. Association of Chronic Kidney Disease with Atrial Fibrillation Among Adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011;4:26-32.
47. Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 2005;98:73-7. (Pubitemid 40169856)
48. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-9.
49. Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010;28:1738-44.
50. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis. Europace 2009;11: 1156-9.
51. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572-7.
52. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: A follow-up study. Europace 2008;10:618-23. (Pubitemid 351775294)
53. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E et al. Sport practice and the risk of lone atrial fibrillation: A case-control study. Int J Cardiol 2006;108:332-7. (Pubitemid 43339799)
54. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J 2006;27:949-53.
55. Mattioli AV, Bonatti S, Zennaro M, Melotti R, Mattioli G. Effect of coffee consumption, lifestyle and acute life stress in the development of acute lone atrial fibrillation. J Cardiovasc Med (Hagerstown) 2008;9:794-8.
56. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr 2010;92: 509-14.
57. Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 2009;301:2571-7.
58. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 2010;121:200-7.
59. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010;56:1712-9.
60. Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E et al. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: Data from the GISSI-Atrial Fibrillation Trial. J Intern Med 2011;269:160-71.
61. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation 2009; 120:1768-74.
62. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J Am Coll Cardiol 2007;50:2021-8. (Pubitemid 350087568)
63. Schnabel RB, Lunetta KL, Larson MG, Dupuis J, Lipinska I, Rong J et al. The relation of genetic and environmental factors to systemic inflammatory biomarker concentrations. Circ Cardiovasc Genet 2009;2:229-37.
64. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 2010;31:1730-6.
65. Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C et al. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: Data from the GISSI atrial fibrillation trial. Heart 2010;96:1909-14.
66. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol 2010;56:789-95.
67. Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM. Birth weight is a significant risk factor for incident atrial fibrillation. Circulation 2010;122:764-70.
68. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY et al. Subclinical atherosclerosis and risk of atrial fibrillation: The Rotterdam study. Arch Intern Med 2007;167:382-7. (Pubitemid 46333939)
69. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. Circulation 2004;109:1267-71. (Pubitemid 38372785)
70. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306: 1018-22. (Pubitemid 12155370)
71. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-37.
72. Spach MS, Heidlage JF, Dolber PC, Barr RC. Mechanism of origin of conduction disturbances in aging human atrial bundles: Experimental and model study. Heart Rhythm 2007;4:175-85. (Pubitemid 46158701)
73. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-5. (Pubitemid 36736633)
74. Rienstra M, Van Veldhuisen DJ, Hagens VE, Ranchor AV, Veeger NJ, Crijns HJ et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: Data of the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol 2005;46:1298-306. (Pubitemid 41615553)
75. Group SiAw. Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 2007;69:546-54.
76. Lane DA, Lip GY. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. Thromb Haemost 2009;101:802-5.
77. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005;105:315-8. (Pubitemid 41605083)
78. Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF. Pitx2 prevents susceptibility to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci USA 2010;107:9753-58.
79. Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH et al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression. Circ Cardiovasc Genet 2011;4:123-33.
80. Baccarelli A, Rienstra M, Benjamin EJ. Cardiovascular epigenetics: Basic concepts and results from animal and human studies. Circ Cardiovasc Genet 2010;3:567-73.
81. Stritzke J, Markus MR, Duderstadt S, Lieb W, Luchner A, Doring A et al. The aging process of the heart: Obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. J Am Coll Cardiol 2009;54:1982-9.
82. Al Chekakie MO, Welles CC, Metoyer R, Ibrahim A, Shapira AR, Cytron J et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol 2010;56:784-8.
83. Batal O, Schoenhagen P, Shao M, Ayyad AE, Van Wagoner DR, Halliburton SS et al. Left atrial epicardial adiposity and atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:230-6.
84. Kodama S, Saito K, Tanaka S, Horikawa C, Saito A, Heianza Y et al. Alcohol consumption and risk of atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2011;57: 427-36.
85. Heeringa J, Kors JA, Hofman A, van Rooij FJ, Witteman JC. Cigarette smoking and risk of atrial fibrillation: The Rotterdam Study. Am Heart J 2008;156:1163-9.
86. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002;23:477-82. (Pubitemid 35204187)
87. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: The cardiovascular health study. Circulation 2008;118:800-7.
88. Mont L, Elosua R, Brugada J. Endurance sport practice as a risk factor for atrial fibrillation and atrial flutter. Europace 2009;11:11-7.
89. Benito B, Gay-Jordi G, Serrano-Mollar A, Guasch E, Shi Y, Tardif JC et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation 2011;123:13-22.
90. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo Diet and Cancer study: A study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol 2010;25:95-102.
91. den Uijl DW, Delgado V, Tops LF, Ng AC, Boersma E, Trines SA et al. Natriuretic peptide levels predict recurrence of atrial fibrillation after radiofrequency catheter ablation. Am Heart J 2011;161:197-203.
92. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009;104:92-6.
93. Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010;104:122-7.
94. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-4. (Pubitemid 27344221)
95. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol 2007;99:1544-8. (Pubitemid 46770639)
96. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-7. (Pubitemid 38842447)
97. Osranek M, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: Three-decade follow-up. Eur Heart J 2005;26:2556-61. (Pubitemid 41679360)
98. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR et al. Prediction of cardiovascular outcomes with left atrial size: Is volume superior to area or diameteř J Am Coll Cardiol 2006;47:1018-23.
99. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ et al. Left atrial size: Physiologic determinants and clinical applications. J Am Coll Cardiol 2006;47:2357-63. (Pubitemid 43866385)
100. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR et al. Prediction of risk for first age-related cardiovascular events in an elderly population: The incremental value of echocardiography. J Am Coll Cardiol 2003;42:1199-205. (Pubitemid 37188341)
101. De Vos CB, Weijs B, Crijns HJ, Cheriex EC, Palmans A, Habets J et al. Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart 2009;95:835-40.
102. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12.
103. Casaclang-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: Clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 2008;51:1-11.
104. Tops LF, Schalij MJ, Bax JJ. Imaging and atrial fibrillation: The role of multimodality imaging in patient evaluation and management of atrial fibrillation. Eur Heart J 2010;31:542-51.
105. Maceira AM, Cosin-Sales J, Roughton M, Prasad SK, Pennell DJ. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:65.
106. Ozgun M, Kirchhof P, Bunck AC, Heindel W, Eckardt L, Maintz D. MRI of right atrial function after catheter ablation of atrial flutter. Acad Radiol 2010;17: 856-61.
107. Anwar AM, Geleijnse ML, Soliman OI, Nemes A, ten Cate FJ. Left atrial Frank- Starling law assessed by real-time, three-dimensional echocardiographic left atrial volume changes. Heart 2007;93:1393-7. (Pubitemid 351480138)
108. Marsan NA, Westenberg JJ, Tops LF, Ypenburg C, Holman ER, Reiber JH et al. Comparison between tissue Doppler imaging and velocity-encoded magnetic resonance imaging for measurement of myocardial velocities, assessment of left ventricular dyssynchrony, and estimation of left ventricular filling pressures in patients with ischemic cardiomyopathy. Am J Cardiol 2008;102:1366-72.
109. Saraiva RM, Demirkol S, Buakhamsri A, Greenberg N, Popovic ZB, Thomas JD et al. Left atrial strain measured by two-dimensional speckle tracking represents a new tool to evaluate left atrial function. J Am Soc Echocardiogr 2010;23:172-80.
110. Van Beeumen K, Duytschaever M, Tavernier R, Van de Veire N, De Sutter J. Intra-And interatrial asynchrony in patients with heart failure. Am J Cardiol 2007;99:79-83. (Pubitemid 44969344)
111. Delgado V, Vidal B, Sitges M, Tamborero D, Mont L, Berruezo A et al. Fate of left atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency catheter ablation for the treatment of atrial fibrillation. Am J Cardiol 2008;101:1285-90.
112. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622-6. (Pubitemid 28273307)
113. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758-67.
114. Ozgun M, Maintz D, Bunck AC, Monnig G, Eckardt L,Wasmer K et al. Right atrial scar detection after catheter ablation: Comparison of 2D and high spatial resolution 3D-late enhancement magnetic resonance imaging. Acad Radiol 2011;18: 488-94.
115. Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S et al. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: Relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging 2010;3:231-9.
116. McGann CJ, Kholmovski EG, Oakes RS, Blauer JJ, Daccarett M, Segerson N et al. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol 2008; 52:1263-71.
117. Badger TJ, Oakes RS, Daccarett M, Burgon NS, Akoum N, Fish EN et al. Temporal left atrial lesion formation after ablation of atrial fibrillation. Heart Rhythm 2009;6:161-8.
118. Akoum N, Daccarett M, McGann C, Segerson N, Vergara G, Kuppahally S et al. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: A DE-MRI guided approach. J Cardiovasc Electrophysiol 2011;22:16-22.
119. Pfeufer A, van Noord C, Marciante KD, Arking DE, Larson MG, Smith AV et al. Genome-wide association study of PR interval. Nat Genet 2010;42:153-9.
120. Magnani JW, Gorodeski EZ, Johnson VM, Sullivan LM, Hamburg NM, Benjamin EJ et al. P wave duration is associated with cardiovascular and all-cause mortality outcomes: The National Health and Nutrition Examination Survey. Heart Rhythm 2011;8:93-100.
121. Holmqvist F, Platonov PG, McNitt S, Polonsky S, Carlson J, Zareba W et al. Abnormal P-wave morphology is a predictor of atrial fibrillation development and cardiac death in MADIT II patients. Ann Noninvasive Electrocardiol 2010;15: 63-72.
122. De Bacquer D, Willekens J, De Backer G. Long-term prognostic value of p-wave characteristics for the development of atrial fibrillation in subjects aged 55 to 74 years at baseline. Am J Cardiol 2007;100:850-4. (Pubitemid 47268278)
123. Jons C, Raatikainen P, Gang UJ, Huikuri HV, Joergensen RM, Johannesen A et al. Autonomic dysfunction and new-onset atrial fibrillation in patients with left ventricular systolic dysfunction after acute myocardial infarction: A CARISMA Substudy. J Cardiovasc Electrophysiol 2010;21:983-90.
124. Kirchhof P, Eckardt L, Franz MR, Mönnig G, Loh P, Wedekind H et al. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003;14:1027-33. (Pubitemid 37412078)
125. Kirchhof P, Eckardt L, Monnig G, Johna R, Loh P, Schulze-Bahr E et al. A patient with 'atrial torsades de pointes'. J Cardiovasc Electrophysiol 2000;11:806-11.
126. Zellerhoff S, Pistulli R, Moennig G, Hinterseer M, Beckmann B-M, Koebe J et al. Atrial arrhythmias in long QT syndrome-a Nested Case Control Study. J Cardiovasc Electrophysiol 2009;20:401-7.
127. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008;5:704-9.
128. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P et al. Short QT syndrome: Clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006;27:2440-7. (Pubitemid 44522151)
129. Gaita F, Giustetto C, Bianchi F,Wolpert C, Schimpf R, Riccardi R et al. Short QT syndrome: A familial cause of sudden death. Circulation 2003;108:965-70. (Pubitemid 37048226)
130. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T et al. Brugada syndrome and supraventricular tachyarrhythmias: A novel association? J Cardiovasc Electrophysiol 2001;12:680-5. (Pubitemid 32506163)
131. Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-4. (Pubitemid 36125211)
132. Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999;340:839-46. (Pubitemid 29142627)
133. Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of hypertrophic cardiomyopathy in Taiwan-a tertiary center experience. Clin Cardiol 2007;30:177-82.
134. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D'Alessandro G et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900. (Pubitemid 39359175)
135. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7. (Pubitemid 34084637)
136. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:905-11. (Pubitemid 27137190)
137. Lubitz SA, Sinner MF, Lunetta KL, Makino S, Pfeufer A, Rahman R et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation 2010;122:976-84.
138. Kaab S, Darbar D, van Noord C, Dupuis J, Pfeufer A, Newton-Cheh C et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 2009;30:813-9.
139. Sinner MF, Lubitz SA, Pfeufer A, Makino S, Beckmann BM, Lunetta KL et al. Lack of replication in polymorphisms reported to be associated with atrial fibrillation. Heart Rhythm 2011;8:403-9.
140. Blana A, Kaese S, Fortmuller L, Laakmann S, Damke D, Bragt KV et al. Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm 2010;7:1862-69.
141. Bedi M, McNamara D, London B, Schwartzman D. Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 2006;3:808-12. (Pubitemid 43960535)
142. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL et al. Longterm progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 2007;115:3050-6. (Pubitemid 46956493)
143. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al. The registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009;11:423-34.
144. Ziegler PD, Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a history of thromboembolic events. Stroke 2010;41:256-60.
145. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-9. (Pubitemid 36397330)
146. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-23.
147. Dorian P, Guerra PG, Kerr CR, O'Donnell SS, Crystal E, Gillis AM et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2009;2:218-24.
148. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011;91:265-325.
149. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66. (Pubitemid 28402090)
150. Sahadevan J, Ryu K, Peltz L, Khrestian CM, Stewart RW, Markowitz AH et al. Epicardial mapping of chronic atrial fibrillation in patients: Preliminary observations. Circulation 2004;110:3293-9. (Pubitemid 39557490)
151. Kumagai K, Khrestian C, Waldo AL. Simultaneous multisite mapping studies during induced atrial fibrillation in the sterile pericarditis model. Insights into the mechanism of its maintenance. Circulation 1997;95:511-21. (Pubitemid 27056221)
152. Kumagai K, Uno K, Khrestian C, Waldo AL. Single site radiofrequency catheter ablation of atrial fibrillation: Studies guided by simultaneous multisite mapping in the canine sterile pericarditis model. J Am Coll Cardiol 2000;36:917-23.
153. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. Highdensity mapping of electrically induced atrial fibrillation in humans. Circulation 1994;89:1665-80. (Pubitemid 24114245)
154. Konings KT, Smeets JL, Penn OC,Wellens HJ, Allessie MA. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 1997;95:1231-41. (Pubitemid 27097835)
155. Kanagaratnam P, Kojodjojo P, Peters NS. Electrophysiological abnormalities occur prior to the development of clinical episodes of atrial fibrillation: Observations from human epicardial mapping. Pacing Clin Electrophysiol 2008;31: 443-53. (Pubitemid 351464691)
156. Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL et al. The electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: Longitudinal dissociation. Circ Arrhythm Electrophysiol 2010;3:606-15.
157. Cuculich PS,Wang Y, Lindsay BD, Faddis MN, Schuessler RB, Damiano RJ Jr et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation 2010;122:1364-72.
158. Guillem MS, Climent AM, Castells F, Husser D, Millet J, Arya A et al. Noninvasive mapping of human atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:507-13.
159. Platonov PG, Nault I, Holmqvist F, Stridh M, Hocini M, Haissaguerre M. Left atrial appendage activity translation in the standard 12-lead ECG. J Cardiovasc Electrophysiol 2011;22:706-10.
160. Nault I, Lellouche N, Matsuo S, Knecht S, Wright M, Lim KT et al. Clinical value of fibrillatory wave amplitude on surface ECG in patients with persistent atrial fibrillation. J Interv Card Electrophysiol 2009;26:11-9.
161. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007;101:839-47. (Pubitemid 350287199)
162. Kalifa J, Tanaka K, Zaitsev AV, Warren M, Vaidyanathan R, Auerbach D et al. Mechanisms of wave fractionation at boundaries of high-frequency excitation in the posterior left atrium of the isolated sheep heart during atrial fibrillation. Circulation 2006;113:626-33.
163. Verheule S, Tuyls E, van Hunnik A, Kuiper M, Schotten U, Allessie M. Fibrillatory conduction in the atrial free walls of goats in persistent and permanent atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:590-99.
164. Eckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, Verheule S et al. Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc Res 2011;89:816-24.
165. Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF, Gutteridge G et al. Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation. Ann Thorac Surg 1995;60:1709-15. (Pubitemid 26079160)
166. Lo B, Fijnheer R, Nierich AP, Bruins P, Kalkman CJ. C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg 2005;79:1530-5. (Pubitemid 40614561)
167. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM et al. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-8. (Pubitemid 27513431)
168. Kaireviciute D, Aidietis A, Lip GY. Atrial fibrillation following cardiac surgery: Clinical features and preventative strategies. Eur Heart J 2009;30:410-25.
169. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-9. (Pubitemid 38489894)
170. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol 2004;43:47-52. (Pubitemid 38045914)
171. Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: A systematic review. Stroke 2007;38:2935-40. (Pubitemid 350035686)
172. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004;35:1647-51. (Pubitemid 38823640)
173. Stahrenberg R, Weber-Kruger M, Seegers J, Edelmann F, Lahno R, Haase B et al. Enhanced detection of paroxysmal atrial fibrillation by early and prolonged continuous holter monitoring in patients with cerebral ischemia presenting in sinus rhythm. Stroke 2010;41:2884-88.
174. Kirchhof P. Can we improve outcomes in atrial fibrillation patients by early therapy? BMC Med 2009;7:72.
175. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005;46:1913-20. (Pubitemid 41579816)
176. Sinha AM, Diener HC, Morillo CA, Sanna T, Bernstein RA, Di Lazzaro V et al. Cryptogenic Stroke and underlying Atrial Fibrillation (CRYSTAL AF): Design and rationale. Am Heart J 2010;160:36-41 e1.
177. Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F et al. Presence and duration of atrial fibrillation detected by continuous monitoring: Crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009;20:241-8.
178. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-80.
179. Healey J, Connolly S, Gold MR, Cappucci A, Israel C, van Gelder IC et al. The relationship between atrial high-rate episodes and stroke: The asymptomatic stroke and atrial fibrillation evaluation in pacemaker patients (ASSERT) trial. Abstract 21838. Circulation 2010;122:2220-21.
180. Boriani G, Botto G, Padeletti L, Santini M, Capucci A, Gulizia M et al. Improving stroke risk stratification using the CHADS2 and CHA2DS2VASc risk scores in paroxysmal atrial fibrillation patients by continuous arrhythmia burden monitoring. Stroke 2011;42:1768-70.
181. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL et al. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/ atrial flutter. Circulation 2009;120:1174-80.
182. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009;11:671-87.
183. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation-results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141-7.
184. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
185. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
186. Connolly S, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
187. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
188. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Prevention of Stroke and Systemic Embolism Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: The ROCKET AF Trial. New Engl J Med, in press.
189. Beasley BN, Unger E, Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of Dabigatran (perspective). N Engl J Med 2011;364:1788-90.
190. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010;376:975-83.
191. De Caterina R, Connolly SJ, Pogue J, Chrolavicius S, Budaj A, Morais J et al. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: Insights from ACTIVE-W. Eur Heart J 2010;31:2133-40.
192. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21.
193. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ 2001;323:1218-22.
194. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
195. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011;57:173-80.
196. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: A systematic review. QJM 2007;100: 599-607. (Pubitemid 47543414)
197. O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 2000;342:240-5. (Pubitemid 30058955)
198. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM.Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology 2000;55:947-51.
199. Rosand J, Greenberg SM. Beyond hypertension: Unraveling the causes of intracerebral hemorrhage. Stroke 2002;33:1195-6. (Pubitemid 34517034)
200. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009;72:1230-5.
201. Smith EE, Gurol ME, Eng JA, Engel CR, Nguyen TN, Rosand J et al. White matter lesions, cognition, and recurrent hemorrhage in lobar intracerebral hemorrhage. Neurology 2004;63:1606-12. (Pubitemid 39507576)
202. Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM et al. Patientspecific decision-making for warfarin therapy in nonvalvular atrial fibrillation: How will screening with genetics and imaging help? Stroke 2008;39:3308-15.
203. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96. (Pubitemid 46842784)
204. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501. (Pubitemid 29482392)
205. Thompson BB, Bejot Y, Caso V, Castillo J, Christensen H, Flaherty ML et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review. Neurology 2010;75:1333-42.
206. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica 2005;35:891-910. (Pubitemid 41759174)
207. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-26. (Pubitemid 37087616)
208. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34. (Pubitemid 41552972)
209. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al. Impact of the type of center on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105: 1010-23.
210. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: The potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost. 2011; 9:441-9
211. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170: 1433-41.
212. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010;103:13-28.
213. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary-A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010;31:1311-8.
214. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E et al. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011;13: 723-46.
215. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Circulation 2011;123: 2363-72.
216. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116-27.
217. Naganuma M, Koga M, Shiokawa Y, Nakagawara J, Furui E, Kimura K et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: The Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis 2011;31:123-9.
218. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33.
219. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An openlabel, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
220. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS et al. Costeffectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011;154:1-11.
221. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009;374:534-42.
222. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
223. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006;367: 1903-12.
224. Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomised, open-label, noninferiority trial. Lancet 2008;371:315-21.
225. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-43.
226. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, Zerm T et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from a 5-year follow-up. Circulation 2010;122:2368-77.
227. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F et al. Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011;57:160-6.